T1	Condition 20 31	intolerance
T2	Procedure 35 49	blood products
T3	Non-query-able 53 140	to one of the components of the study product or is unwilling to receive blood products
R1	AND Arg1:T1 Arg2:T2	
T4	Pregnancy_considerations 143 234	Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing
T5	Post-eligibility 237 379	Subject is currently participating or plans to participate in any other investigational device or drug without prior approval from the Sponsor
T6	Person 429 441	drug abusers
T7	Person 414 421;434 441	alcohol abusers
*	OR T6 T7
T8	Procedure 465 479	trauma surgery
T9	Non-query-able 481 605	Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
T10	Condition 621 624	TBS
T11	Qualifier 656 678	Class III Contaminated
T12	Qualifier 682 708	Class IV Dirty or Infected
*	OR T11 T12
T13	Scope 656 708	Class III Contaminated or Class IV Dirty or Infected
R2	Has_scope Arg1:T10 Arg2:T13	
T14	Non-query-able 711 987	TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the EVARREST™ or SURGICEL® to blood flow and pressure during healing and absorption of the produc
T15	Condition 991 994	TBS
T16	Condition 1000 1023	major arterial bleeding
T17	Procedure 1044 1063	mechanical ligation
T18	Procedure 1034 1040	suture
*	OR T18 T17
T19	Scope 1034 1063	suture or mechanical ligation
R3	AND Arg1:T15 Arg2:T16	
R4	Has_scope Arg1:T16 Arg2:T19	
T20	Non-query-able 1066 1156	Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine
